Childhood Cancer Research Stalls Amid Broad Scientific Disruptions

When Ryleigh Schecter answered the front door of her home in Twinsburg, Ohio, she was wearing an oversized lavender bow in her hair that matched the stripes on her shirt. “Rainbow” is her favorite color, she told visitors as she sat with her parents, Amanda and Aaron, in their living room. To prove it, she recited the colors of the spectrum in order, adding “pink, silver, gold” at the end. She is 5 years old.
Eventually, the conversation turned to the medicine she takes every night. On cue, Ryleigh sped to the kitchen and raced back carrying a sandwich bag full of Skittles containing only the red, orange, and yellow candies. “I don’t like the purple or the green,” she explained.

Ryleigh takes two drugs every evening, one of which is designed to treat breast cancer. Her mother mixes them as if from a chemistry set and administers them orally using a syringe. Ryleigh detests the routine. “The first one tastes disgusting, and the second one tastes medium,” she told visitors, describing the initial dose as tasting like “dirty water mixed together.” After each dose, Ryleigh eats a Skittle to wash away the taste, with orange being her preferred flavor.
The family’s daily regimen unfolds against a backdrop of broader national hurdles affecting scientific discovery. The situation forms part of a series examining disruption to research and discovery under Trump, highlighting how investigations into a fatal pediatric cancer that typically claims young lives within a year have stalled for a full year.